Evidence map›Paper›PMID 31159359›Full record

ReviewMarine drugs2019

Prebiotics from Seaweeds: An Ocean of Opportunity?

Paul Cherry, Supriya Yadav, Conall R Strain, Philip J Allsopp, Emeir M McSorley, R Paul Ross, Catherine Stanton

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 136 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Commercial importance of seaweeds: an overview.Bioresources and bioprocessing · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. No colonization resistance toFrontiers in microbiology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Paul CherryNutrition Innovation Centre for Food and Health, Ulster University, Cromore Road, Coleraine, Co. Londonderry BT52 1SA, UK. paul.cherry@ucc.ie.
Supriya YadavTeagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, P61 C996, Ireland. 18supriya@gmail.com.
Conall R StrainTeagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, P61 C996, Ireland. conall.strain@teagasc.ie.
Philip J AllsoppNutrition Innovation Centre for Food and Health, Ulster University, Cromore Road, Coleraine, Co. Londonderry BT52 1SA, UK. pj.allsopp@ulster.ac.uk.
Emeir M McSorleyNutrition Innovation Centre for Food and Health, Ulster University, Cromore Road, Coleraine, Co. Londonderry BT52 1SA, UK. em.mcsorley@ulster.ac.uk.
R Paul RossAPC Microbiome Ireland, University College Cork, Cork T12 YT20, Ireland. p.ross@ucc.ie.
Catherine StantonTeagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, P61 C996, Ireland. catherine.stanton@teagasc.ie.
Teagasc - The Irish Agriculture and Food Development Authority · IEUniversity of Ulster · GBUniversity College Cork · IE

Funding

The Department of Agriculture Food and the Marine (FIRM) 13F511
6 · The paper itself

Abstract

Seaweeds are an underexploited and potentially sustainable crop which offer a rich source of bioactive compounds, including novel complex polysaccharides, polyphenols, fatty acids, and carotenoids. The purported efficacies of these phytochemicals have led to potential functional food and nutraceutical applications which aim to protect against cardiometabolic and inflammatory risk factors associated with non-communicable diseases, such as obesity, type 2 diabetes, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and some cancers. Concurrent understanding that perturbations of gut microbial composition and metabolic function manifest throughout health and disease has led to dietary strategies, such as prebiotics, which exploit the diet-host-microbe paradigm to modulate the gut microbiota, such that host health is maintained or improved. The prebiotic definition was recently updated to "a substrate that is selectively utilised by host microorganisms conferring a health benefit", which, given that previous discussion regarding seaweed prebiotics has focused upon saccharolytic fermentation, an opportunity is presented to explore how non-complex polysaccharide components from seaweeds may be metabolised by host microbial populations to benefit host health. Thus, this review provides an innovative approach to consider how the gut microbiota may utilise seaweed phytochemicals, such as polyphenols, polyunsaturated fatty acids, and carotenoids, and provides an updated discussion regarding the catabolism of seaweed-derived complex polysaccharides with potential prebiotic activity. Additional in vitro screening studies and in vivo animal studies are needed to identify potential prebiotics from seaweeds, alongside untargeted metabolomics to decipher microbial-derived metabolites from seaweeds. Furthermore, controlled human intervention studies with health-related end points to elucidate prebiotic efficacy are required.

Indexed as

PrebioticsAnimalsAquatic OrganismsGastrointestinal MicrobiomeHumansPhytochemicalsSeaweedPhytochemicalsPrebioticscarotenoidscomplex polysaccharidesdietary fibregut microbiotaphytochemicalspolyphenolspolyunsaturated fatty acidsprebioticsseaweed

Identifiers

PMID31159359
PMCPMC6627129
OpenAlexW2947820858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.